Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016 is a new market research publication announced by Reportstack. This report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the ovarian cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Ovarian Cancer which mainly describes the treatment of ovarian cancer at different stages. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries. It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK.
This report provides the insights of the marketed medicines for the Ovarian Cancer which includes the Targeted Therapy and Chemotherapy. These days’ companies are focusing on the Targeted Therapy for cancer. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. All are in preregistration stage. Along with the Targeted Therapy, this report also provides the landscape of Chemotherapy available for the Ovarian Cancer. This report also covers the comparison of the Targeted Therapy and Chemotherapy which provides the insights for the marketed medicines.
To view the table of contents and know more details, please visit Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016.
• The new report, provides a Ovarian Cancer Treatment Landscape across the globe
• The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide market barriers, market drivers and opportunities
• Provides Phase III products assessment by monotherapy and combination therapy products, and molecule type.
AbbVie Inc. • Oasmia Pharmaceutical AB • Merck KGaA • Novartis Pharmaceuticals • Baxter Oncology • Medison Pharma • Orion Pharmaceuticals • Merck KGaA
Manager - Marketing
Reportstack Market Research